Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade

Romain Banchereau,1 Avantika S. Chitre,2 Alexis Scherl,3 Thomas D. Wu,4 Namrata S. Patil,1 Patricia de Almeida,2,5 Edward E. Kadel, III,1 Shrvan Madireddi,2 Amelia Au-Yeung,6 Chikara Takahashi,6 Ying-Jiun Chen,7,8 Zora Modrusan,7 Jacqueline McBride,6 Rhea Nersesian,1 Ehab A. El-Gabry,9 Mark D. Robida,9 Jeffrey C. Hung,3 Marcin Kownatz,1,10 Wei Zou,11 Mark McCleland,1 Patrick Caplazi,3 Shadi Toghi Eshgi,6 Hartmut Koeppen,3 Priti S. Hegde,12 Ira Mellman,2 W. Rodney Mathews,6 Thomas Powles,13 Sanjeev Mariathasan,1 Jane Grogan,2 William E O’Gorman1 6

ABSTRACT

Background CD8+ tissue-resident memory T (T_{TRM}) cells, marked by CD103 (ITGAE) expression, are thought to actively suppress cancer progression, leading to the hypothesis that their presence in tumors may predict response to immunotherapy.

Methods Here, we test this by combining high-dimensional single-cell modalities with bulk tumor transcriptomics from 1868 patients enrolled in lung and bladder cancer clinical trials of atezolizumab (anti-programmed cell death ligand 1 (PD-L1)).

Results ITGAE was identified as the most significantly upregulated gene in inflamed tumors. Tumor CD103+ CD8+ T_{TRM} cells exhibited a complex phenotype defined by the expression of checkpoint regulators, cytotoxic proteins, and increased clonal expansion.

Conclusions Our analyses indeed demonstrate that the presence of CD103+ CD8+ T_{TRM} cells, quantified by tracking intratumoral CD103 expression, can predict treatment outcome, suggesting that patients who respond to PD-1/PD-L1 blockade are those who exhibit an ongoing antitumor T-cell response.

INTRODUCTION

Checkpoint therapies can induce potent and durable clinical responses in subsets of patients with cancer across multiple indications. Treatment regimens targeting programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) disrupt an inhibitory signaling program in T cells that reduces their cytolytic activity.1 Thus, blockade of PD-1/PD-L1 binding has been hypothesized to result in the reinvigoration of these T cells and their subsequent killing of tumor cells. While a subset of patients achieve robust antitumor responses with these therapies, many do not, with minimal response rates of 20%–30% across indications such as melanoma, non-small cell lung, urothelial, head and neck, gastrointestinal, and hepatocellular cancers.2 As such, the variability in clinical response to checkpoint inhibitors has generated interest in the heterogeneity and function of the intratumoral T cells critical for efficacy.3 Much attention has been paid to an ‘exhausted’ population of CD8+ T cells that exhibit multiple checkpoint regulators and are presumed to have diminished effector function due to chronic antigen exposure.1 However, the relationship between exhaustion and response to checkpoint blockade is controversial. While some studies correlate exhaustion to poor clinical outcomes,4–9 others have defined a subpopulation of CD103+ CD8+ tissue-resident memory T (T_{TRM}) cells that appear exhausted, but are also proliferative and associate with cancer survival.10

T_{TRM} cells are a specialized population of T cells responsible for the rapid initiation of local immune responses within epithelial tissues, thereby providing protective immunity against invading microbes.11 T_{TRM} cells are broadly distributed in adult human tissues such as the skin, lungs, intestines, and brain.12 13 Furthermore, T_{TRM} cells have been implicated in mediating proinflammatory responses in autoimmune diseases such as psoriasis, alopecia areata, vitiligo, as well as ulcerative colitis.14 15 T_{TRM} cells are defined phenotypically by their expression of CD103 (integrin αE or ITGAE), which pairs with integrin β7 to form the αEβ7 heterodimer.16–18 αEβ7 is exclusively expressed in immune cells and binds to the epithelial protein E-cadherin, mediating intraepithelial lymphocyte localization.19 20

CD103+ T_{TRM} cells play an essential role in limiting tumor growth20 21 as well as in immune surveillance of solid tumors.22 23
Consistent with these observations, tumor infiltration with CD103+ TRM cells has been associated with better clinical outcomes in patients with lung, bladder, endometrial, gastric, and colorectal cancers receiving standard of care therapies.10 22 24–28 Furthermore, CD103+ CD8+ T cells have been shown to preferentially localize in tumor epithelium compared with the surrounding stroma, with better patient outcomes observed with elevated TRM cell frequency within tumor nests.28–30 Expression of CD103 by TRM cells is primarily induced by exposure to tissue-derived cytokines such as tumor growth factor β and interleukin-15.31–34 However, it has been reported that T-cell receptor (TCR) engagement is also necessary to induce CD103 upregulation.35 36 Thus, CD103+ tumor-infiltrating T cells may be the progeny of lymph node-activated and recirculating T effector (TEFF) or T stem-infiltrating (TRM) cells that have recently migrated into tumor tissues and differentiated as a result of exposure to these cytokines and tumor antigens.37

Elevated expression of immune checkpoint regulators such as PD-1 and TIM3 as well as enhanced proliferation (Ki-67) and activation (CD38) markers indicate that TRM cells have the potential to actively limit tumor growth and play a key role in the response to cancer immunotherapy.38 In addition, CD103+ CD8+ cells that coexpress CD39 (ENTPD1) have been found to be uniquely tumor reactive, while their CD39- counterparts are considered ‘bystander’ cells, often bearing TCRs specific for microbial antigens.39 40 However, this observation remains controversial as other studies have found shared TCR clonotypes across different CD8+ T-cell subsets, implying ongoing differentiation between phenotypes within the tumor.41 Importantly, CD39 expression also defines CD8+ T-cell clonotypes in tumors that are expanded and presumptively activated following anti-PD-1 therapy.39 41 It thus seems possible that CD103+ TRM cells are poised to respond to PD-1/PD-L1 blockade.42 One recent study has demonstrated an association between the presence of CD103+ CD8+ T cells in lung tumors and patient response to checkpoint blockade.15 However, the hypothesis that immune CD103 expression in tumors is predictive of response to cancer immunotherapy has not been comprehensively evaluated in large randomized clinical trials.

Our previous studies have identified clonally expanded CD8+ T-effector (TEff) cells in blood with shared clonotypes across both tumor and adjacent non-neoplastic tissues, suggesting that antitumor immunity is characterized by a continuous production of reactive T cells at sites external to the tumor.43 These peripherally expanded T-effector cells shared clonotypes with tumor TRM cells, indicating differentiation of peripheral TEff into TRM following migration into the tumor. Here, we expand on these studies by focusing on intratumoral TRM cells and probe the relationships between CD8+ T-cell tumor infiltration, phenotype, proliferation, and clonal expansion using multidimensional approaches. Our analysis of a cohort of 1868 patients treated with the anti-PD-L1 antibody atezolizumab reveals that CD103 expression does indeed closely correlate with response to immunotherapy and highlights CD8+ TRM as a critical player in the antitumor response.

**Materials and Methods**

**Human subjects**

Samples analyzed from clinical trials were collected as prescreening biopsies obtained from archived paraffin-embedded tissue. Patients were required to have tissue sent to the central laboratory prior to entry into the study. Samples were processed at the time of screening. Tissue samples from three clinical trials were used for these analyses: (1) OAK (NCT02008227), a phase III randomized study comparing atezolizumab (anti-PD-L1 antibody, 1200 mg every 3 weeks) with docetaxel in patients with non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy; (2) IMvigor210 (NCT02108652), a single-arm phase II study investigating atezolizumab (1200 mg every 3 weeks) in patients with metastatic urothelial carcinoma (mUC); and IMvigor211 (NCT02302807), a phase III two-arm, randomized, controlled study comparing atezolizumab (1200 mg every 3 weeks) with chemotherapy (docetaxel, paclitaxel, or vinflunine) in subjects with locally advanced or mUC who have progressed during or following a platinum-containing regimen. Fresh tumor samples and matched adjacent non-cancerous tissues were procured from a commercial vendor (Discovery Life Sciences) as part of adult patients undergoing surgical resection. Online supplemental table S1 provides details for each individual sample such as age, gender, ethnicity, tumor stage, tumor histology subtype (if known), tumor area category (if known), extent of lymph node spread (if known), and metastatic status (if known). Adjacent tissue was required to be more than 0.5 cm away from the tumor and defined as being free of disease morphology at the discretion of the pathologist.

**Statistical analysis**

Comparisons across patient subgroups for ITGAE or CD103 immunohistochemistry (IHC) across CD8+ infiltration status (desert, excluded, and inflamed) as well as ITGAE by PD-L1 levels on immune cells (IC score) were completed using a Kruskal-Wallis test with a Dunn post hoc test adjusted with Benjamini-Hochberg correction for multiple comparisons. For statistical analysis of markers measured by mass cytometry between CD103+ and CD103- CD8+ subpopulations, a two-way analysis of variance with Bonferroni correction for multiple comparisons was used. Correlation of PD-L1 by mass cytometry with various gates of CD8+ T cells was assessed by a Spearman rank test. Statistical significance of differences in overall survival (OS) between patient groups subdivided by gene (ITGAE and CD8A) or protein (CD103) expression was determined by Cox proportional hazard modeling. For all statistical analyses, a p-value of <0.05 was indicated by ‘*’, p<0.01 by ‘**’, p<0.001 by ‘***’,
RESULTS

Cohort characteristics

Clinical and biomarker data were obtained from 1868 patients within three clinical trials in two cancer indications assessing the clinical benefits of PD-L1 blockade with atezolizumab: IMvigor210—a single-arm, phase II study of atezolizumab in patients with first-line (n=95) or second-line (2L+, n=259) locally advanced or mUC; IMvigor211—a two-arm, phase III randomized study in patients with 2L locally advanced or mUC comparing atezolizumab to chemotherapy; and OAK—a two-arm, phase III randomized study in patients with 2L NSCLC comparing atezolizumab to docetaxel. IHC for PD-L1 and CD8 as well as a bulk RNAseq analysis was performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue obtained prior to administration of atezolizumab.

In parallel, independently of the clinical trials, six NSCLC and three endometrial tumor samples were procured as fresh tissue and both tumor and non-cancerous tumor-adjacent tissue were analyzed by mass cytometry, scRNAseq, and scTCRseq upon dissociation. Patient clinical and demographic information for these samples is detailed in online supplemental table S1.

Tumors with high CD8+ T-cell infiltration are enriched in CD103 (ITGAE) expression

Solid tumors have been categorized into inflamed, excluded, and desert phenotypes based on CD8+ T-cell infiltration patterns. In inflamed tumors, CD8+ T cells penetrate tumor nests, while they are largely confined to the tumor stroma in excluded tumors. Tumors devoid of or with extremely low levels of CD8+ T cells are termed immune deserts. Transcriptional comparison of inflamed versus excluded tumors in IMvigor210 revealed 759 genes significantly overexpressed (adjusted p<0.05) in inflamed relative to excluded tumors, with ITGAE appearing as one of the most highly significant genes (p=3.35×10−18) (figure 1A and online supplemental data file S1). Other notable CD8+ T cell-associated genes such as CD8A, IFNG, and LAG3 were also upregulated in inflamed tumors. Expression of the hallmark interferon (IFN)-inducible gene GBP1 was also strongly associated with CD8 phenotype, indicative of ongoing IFN signaling in highly infiltrated tumors. Consistent with these findings and as expected, transcripts associated with T-cell cytokine production and activation pathways were significantly enriched in inflamed tumors, including type I and type II IFN as well as TCR and costimulation pathways (figure 1B).

Identification of the top 25 transcripts correlated with ITGAE expression in IMvigor210 yielded key genes associated with the TRM phenotype as well as IFN-γ signaling (figure 1C). CD8A and ZNF683, which encodes HOBIT, a master regulator of TRM differentiation, were highly correlated with ITGAE, suggesting that CD8+ T RM cells are likely the primary source of ITGAE in bulk tumor transcriptions. ITGAE was highly correlated with FASLG, which is associated with TCR activation and can also be transcriptionally induced by type I IFN signaling. Furthermore, ITGAE was also strongly correlated with the immune checkpoints LAG3 and PDCD1 (PD-1), as well as IFNG, the IFN-inducible gene GBP5, and IFN-γ-induced chemokines (CXCL9, CXCL10, and CCL5). Regulators of cytotoxic degranulation (NK7G) and genes encoding cytotoxic proteins (PRF1, GZMA, GZMH, and GZMB) were also associated with ITGAE.

Increased ITGAE expression within inflamed tumors, relative to excluded and desert tumors, was observed in OAK (NSCLC, p=3.91×10−42), IMvigor210 (mUC, p=1.78×10−27), and IMvigor211 (mUC, p=8.58×10−54) (figure 1D). ITGAE expression was also positively associated with PD-L1 levels on immune cells (IC score), a previously established biomarker of response to immunotherapy, in all three trials (figure 1E). These observations were confirmed at the protein level by IHC for CD103 in FFPE tumor biopsies taken from a subset of patients from IMvigor210. Figure 1F shows representative images of hematoxylin-and-eosin (H&E) stained slides, and IHC for CD8 and CD103 performed on adjacent sections from tumor biopsies that correspond to each infiltration phenotype. Automated image analysis was used to quantify the prevalence of CD103+ cells within manually annotated tumor regions of interest. Supporting transcriptional observations, we found that CD103 staining was enriched in inflamed tumors relative to immune desert and excluded tumors (figure 1G). In summary, tumors infiltrated with CD8+ T cells expressed elevated levels of ITGAE/CD103 and were enriched in genes associated with TCR activation.

Banchereau R, et al. J Immunother Cancer 2021;9:e002231. doi:10.1136/jitc-2020-002231
Intratumoral CD103+ CD8+ T cells express multiple immune checkpoints and Ki-67

To assess the prevalence, distribution, and phenotypes of CD103+ immune cells, a 38-parameter mass cytometry panel (online supplemental table S2) was applied to freshly dissociated tumors as well as non-cancerous tumor-adjacent tissue from six NSCLC and three patients with endometrial cancer. CD45+ cells from NSCLC tumors were merged to create a single UMAP of the immune microenvironment (figure 2A, left). T cells, B cells, NK cells, dendritic cells, macrophages, and neutrophils were identified with manual gates and projected onto the UMAP as previously described. CD103 expression was primarily restricted to the CD8+ T-cell lineage but was also detectable in rare CD4+ T-cell and NK-cell subsets (figure 2A, right). Similar results were obtained for endometrial tumors (online supplemental figure S1A).

Manual gating analysis was performed on all tumors to quantify (1) the total immune cell composition for each tumor (online supplemental figure S1B, left), (2) the percentage of total CD103 expression attributable to each cellular lineage (figure 2B) and (3) the percent of cells expressing CD103 within each immune subpopulation (online supplemental figure S1B, right). As previously described in NSCLC and bladder cancer, while a small
subset of NK cells and CD4+ T cells express CD103, CD8+ T cells accounted for the majority of CD103+ immune cells in the tumor microenvironment (mean of 74%, range of 67%–85%).

Given the predominant expression of CD103 in CD8+ T cells and recent evidence that T_RM cells play a role in tumor immunity,53 CD8 subsets were further investigated. CD8+ T cells from all samples were manually gated and merged to create a UMAP, revealing two major CD8+ T-cell populations...
segregated by CD103 that were observed across all tumors analyzed (UMAPs by individual in online supplemental figure S1C, NSCLC tumors in figure 2C, and endometrial tumors in online supplemental figure S1D). Elevated expression of proliferation (Ki-67), activation (CD38), and immune checkpoint (CTLA-4, TIGIT, TIM3, and PD-1) markers was observed in CD103+ cells. In contrast, CD103− cells expressed higher levels of CD28, Eomesodermin (EOMES), and CD57. CD28 has been proposed as a marker of stem-like T cells based on TCF-1 and CD45RO expression in the context of renal cell carcinoma.40

We further quantified phenotypic differences between CD103+ and CD103− immune cells in tumors as well as non-cancerous tumor-adjacent tissue using manual gating analysis (figure 2D). CD103+ CD8+ T cells in the tumor were significantly enriched for Ki-67, CD38, CTLA-4, TIM3, and PD-1 expressing cells compared with CD103− CD8+ T cells. Few CD8+ T cells were found to express Ki-67, CD38, and CTLA-4 in adjacent tissue regardless of their CD103 phenotype, implying these markers may be associated with tumor-specific activation rather than exclusively being a result of their T RM lineage. On the other hand, PD-1 was also elevated in CD103+ cells from adjacent tissues, suggesting some markers represent a tissue-specific rather than tumor-specific phenotype. In contrast, expression of CD28, EOMES, and CD57 were enriched in CD103− relative to CD103+ cells in both tumor and tumor-adjacent tissues. CD28 and EOMES are hallmarks of an effector memory CD8+ phenotype, with EOMES suppressing T RM differentiation.10,59 The enrichment for EOMES and CD57 in CD103− cells that expressed lower levels of inhibitory receptors was still somewhat unexpected as these markers also typically signify exhausted3 and senescent56 states, respectively. While both exhaustion and senescence are characterized by reduced effector function, the molecular pathways involved in these processes have been shown to differ.57

The percentage of total CD8+ T cells was not significantly correlated with PD-L1 expression on immune cells (CD45+) (online supplemental figure S1E). However, the frequency of CD103+ CD8+ T cells, and especially Ki-67+ CD103+ CD8+ cells, was significantly correlated with PD-L1 positivity on tumor-associated immune cells (p=0.0214 and p=0.0013, respectively), suggesting that this subpopulation could be responsible for inducing PD-L1 expression in the tumors microenvironment, for example, via the release of effector cytokines (eg, IFN-γ) that drive its expression.38

The association of CD103 expression with these phenotypic markers was also analyzed for CD4+ T cells as well as NK cells in tumor and tumor-adjacent tissue (online supplemental figure S2A,B). A smaller fraction of CD4+ T cells expressed CD103 (mean of 8.55% in tumor, 13.3% in adjacent) relative to the levels found in CD8+ T cells, consistent with previous observations.59 In CD4+ T cells overall, Ki-67, CD38, CTLA-4, and TIGIT expressions were elevated in tumor relative to adjacent tissue, but these differences were not stratified by CD103 expression. Only EOMES and CD57 were elevated specifically in tumor CD103+ CD4+ T cells, the inverse of what was seen in tumor CD8+ T cells. NK cells were detected at low frequencies in tumor tissue and showed high variability in CD103 positivity (online supplemental figure S2B). CD57 was the only marker that matched what was observed for CD8+ T cells in the tumor for NK cells, where it was enriched in CD103− relative to CD103+ subpopulations; however, this was the case in adjacent tissue as well. In NK cells from adjacent tissue, significant differences based on CD103 expression were found for CD38, TIM3, and PD-1. Overall, CD8+ T cells were the most abundant CD103+ cell population we observed, and the presumably tumor-specific activated phenotype of CD103+ CD8+ T cells most likely reflects in vivo TCR triggering by tumor antigens.

CD8+ T RM cells coexpress genes associated with dysfunction and cytotoxicity

In order to further characterize tumor CD8+ T-cell diversity and clonality, scRNAseq and scTCRseq were applied to a subset of the same samples analyzed by mass cytometry (NSCLC n=3, endometrial n=3). A UMAP was generated for tumor CD8+ T cells and annotated using cluster designators we previously defined (figure 3A).44 Eight clusters were identified, capturing effector T cells (T Eff, 8.1), effector memory T cells (T RM, 8.2), T RM cells (8.3a-c), cells experiencing chromatin remodeling (8.4), mitotic cells (8.5), and KLRB1-expressing cells (8.6). Cluster annotations were cross-referenced with previous publications that revealed similar subpopulations with well-correlated gene signatures.44 T RM cells were the predominant CD8+ cell type present in the tumor, with 52.6% of cells falling in the 8.3a-c clusters combined (figure 3B, left panel, individual frequencies depicted in the right panel). Hierarchical clustering was used to visualize differential gene expression between clusters (figure 3C). 8.1-T Eff cells were largely defined by the expression of the cytotoxic proteins GZMB, GZMH, and PRF1, as well as low levels of immune checkpoint regulators. Distinctively high levels of GZMK were observed in 8.2-T RM along with coexpression of TNF, CD27, CD28, and EOMES, indicative of an effector memory phenotype.58

The cluster identified as 8.4-Chrom was previously characterized as being involved in chromatin remodeling and ongoing histone modification, as evidenced by expression of chromatin remodeling enzyme CHD1 and long non-coding RNA MALAT1, which directly binds components of the chromatin remodeling complex.62 The 8.6-KLRB1 cluster exhibited uniquely high levels of KLRB1, along with TCF7, CCR7, and IL7R, indicating the possibility that this cluster represents T RM cells, a population thought to be essential for response to checkpoint inhibition when harboring TCRs specific to tumor antigens.63 Importantly, 21% of cells in cluster 8.6 expressed the TRAV1-2 conserved TCR domain, which is a marker of the mucosal associated invariant T-cell lineage, thus suggesting even deeper phenotypic diversity within this cluster.44

Three distinct T RM clusters (8.3a-c) were found to be stratified by a stepwise increase in ITGA8 along with immune checkpoint regulators, IFNG, CXCL13, and multiple cytotoxic proteins (figure 3C). ZNF683, the gene encoding HOBIT, was expressed in all three...
clusters but appeared highest in 8.3a and 8.3b. T<sub>RM</sub> clusters 8.3a could represent a transitional state between progenitor phenotypes and T<sub>RM</sub> differentiation as tissue residency and stem-like markers (e.g., IL7R) overlapped in this population. T<sub>RM</sub> cluster 8.3a may also be resting T<sub>RM</sub> bystander cells. Relatedly, the transcription factor TOX
has emerged as a master regulator of exhaustion; thus, its expression is capable of delineating chronically activated tumor antigen-specific T cells from bystanders.\(^\text{65,66}\) Importantly, TOX programming also inhibits clonal deletion, enabling cellular persistence.\(^\text{66}\) TOX expression was absent in cluster 8.3a but increased progressively in clusters 8.3b and 8.3c. As anticipated by recent studies, TOX expression in 8.3b and 8.3c overlapped with phenotypic markers of T-cell dysfunction as well as the ATPase ENTPD1 (CD39), another putative marker of tumor-specific CD8+ T cells.\(^\text{35}\)

Our mass cytometry analysis demonstrated that a subset of CD103+ CD8+ T cells displayed Ki-67 expression (figure 2C,D), suggesting a proliferative state. While cluster 8.3a-c did not express MKI67, a separate cluster 8.5 expressed high levels of MKI67 and also had the highest expression of ITGAE across all clusters, as well as robust expression of checkpoint molecules, TOX, and ENTPD1 (figure 3C). Importantly, these mitotic T\(_{\text{RM}}\) cells also displayed elevated expression of IFNG, the TCR activation-specific marker TNFRSF9 (4-1BB), and CXCL13, which collectively may signify response to tumor antigens in vivo prior to tumor excision.

In order to precisely assess the relationship between CD103 and CD39 expression, mass cytometry was applied to a pair of matched NSCLC tumor and adjacent tissue samples (online supplemental figure S3A). Like Ki-67, CD39 was selectively expressed on intratumoral CD103+ cells, with fivefold less CD39+ CD103+ cells detected in the adjacent tissue (online supplemental figure S3B). Furthermore, manual gating analysis showed that CD39+ CD8+ T cells were a subset of CD103+ cells (online supplemental figure S3C). Ki-67 and checkpoint regulators were enriched in CD103+ CD39+ cells relative to CD103+ CD39- cells (online supplemental figure S3D,E). CD103- CD39- T cells exhibited the lowest frequency of positivity for these markers and instead were elevated in positivity for CD28, EOMES, and CD57 (online supplemental figure S3D,E).

Transcript levels for specific genes of interest were displayed via UMAP in order to visualize their expression with single-cell resolution (figure 3D and online supplemental figure S4A). ITGAE, ZNF683, and ENTPD1 were most localized in the T\(_{\text{RM}}\) and mitotic clusters. T\(_{\text{RM}}\) clusters were enriched in checkpoint regulators, IFNG, CXCL13, and cytotoxicity mediators (eg, GZMH, GZMA, and GZMB), whereas MKI67 positivity was only observed in the mitotic subset of T\(_{\text{RM}}\) (8.5). Conversely, GZMK was expressed outside of T\(_{\text{RM}}\) clusters in T\(_{\text{RM}}\) cells (online supplemental figure S4A). Online supplemental figure 4 depicts UMAP visualizations for additional genes of interest that were presented in our heatmap and mass cytometry analyses.

**Tumor T\(_{\text{RM}}\) cells exhibit clonal expansion**

Single-cell TCR clonality analysis was then performed to associate cellular phenotypes with patterns of clonal expansion. Overlaying clone size onto the UMAP (represented by both data point size and color), we observed that cells with high degrees of clonal expansion were mostly localized in the 8.3c-T\(_{\text{RM}}\) cluster (figure 3E). Comparing gene expression to clone size in a quantitative manner, we found that T\(_{\text{RM}}\)-associated genes (ITGAE, ITG77, and ZNF683) were most expressed in expanded clonotypes (figure 3F). Expression of checkpoints, cytotoxic molecules, and proinflammatory cytokines appeared highest in these clones, although they were also detected to a lesser extent on smaller clonotypes. In contrast, GZMK (figure 3F) along with genes associated with a naive or stem-like T-cell state (IL7R, CCR7, and TCF7) (online supplemental figure S4B) were primarily expressed in cells with the least number of clones.

TCR clonotype sharing between clusters (light gray columns) was broadly observed, although with variable frequency, suggesting phenotypic plasticity (online supplemental figure S4C). Clusters 8.3b and 8.3c shared TCRs, indicating potential intratumoral lineage differentiation. However, some clones (black columns) were more restricted to specific clusters. Importantly, mitotic cluster 8.5 shared clonotypes primarily with the T\(_{\text{RM}}\) clusters, further supporting the relationship between in vivo proliferation and the tissue-resident phenotype. Taken together, this suggests that the previously identified TCR activation signatures in inflamed tumors (figure 1B) and CD8+ T\(_{\text{RM}}\)-specific Ki-67 expression (figure 2D) can result in T\(_{\text{RM}}\) cell proliferation in vivo. Furthermore, increased cytolytic protein expression in T\(_{\text{RM}}\) cells as a function of clonal expansion may reflect the ability of these cells to control tumor growth, as has been described in preclinical models.\(^\text{20,21}\) These observations are aligned with previous scRNAseq analyses of the lung,\(^\text{67}\) and skin\(^\text{68,69}\) tumor microenvironment with the additional insight provided here that the cell populations annotated as exhausted in these previous studies are most likely T\(_{\text{RM}}\) cells.

Reanalysis of a recently published scRNAseq dataset of T cells in bladder cancer\(^\text{46}\) identified a CD8+ T-cell subpopulation expressing CD39 transcripts (annotated as CD8+CD39+) that closely resembled the phenotype we observed in 8.3c-T\(_{\text{RM}}\) cells (comparative cluster analysis in online supplemental figure S5A). In addition, this study also found a proliferative CD8+ population that correlated to the mitotic T\(_{\text{RM}}\) cells in cluster 8.5 (online supplemental figure S5A,B). However, relative frequencies of the various CD8+ clusters differed from our observations in NSCLC (online supplemental figure SSC).

**ITGAE/CD103 expression predicts clinical response to immunotherapy**

The association between ITGAE expression in pretreatment tumor biopsies and overall survival (OS) was assessed in the OAK, IMvigor210, and IMvigor211 cohorts. In OAK, increased OS was observed in ITGAE\(^\text{high}\) tumors from patients treated with atezolizumab but not chemotherapy (figures 4A and online supplemental figure S6A), with CD8A behaving similarly. When looking at the prognostic capacity of ITGAE in mUC, we again observed that...
ITGAE/CD103 expression is predictive of response to PD-L1 blockade. (A) Kaplan-Meier curves depicting the OS probability of patients with locally advanced or metastatic NSCLC cancer treated with atezolizumab (red) or chemotherapy (blue) (OAK) categorized by high (solid line) or low (dotted line) transcriptional expression (median cut-off) of either ITGAE (left panel) or CD8A (right panel). P-values are displayed within each panel. (B) Kaplan-Meier curves demonstrating OS in patients with mUC from IMvigor210 categorized by high (red) or low (blue) transcriptional expression (median cut-off) of either ITGAE (left panel) or CD8A (right panel). HRs and p-values are shown for each gene. (C) Distribution of CD103+ cells in the tumor area across a subcohort (n=91) of IMvigor210 biopsies stained for CD103 by IHC. The dotted line indicates the 2% cut-off defining CD103\textsuperscript{high} and CD103\textsuperscript{low} patient groups. (D) Correlation of gene expression of ITGAE, as measured by bulk RNAseq analysis (TPM, y-axis), to quantification of CD103 protein by IHC (frequency of positive events out of total cells in tumor area, x-axis) for the subset of IMvigor210 patient samples analyzed. The Spearman R correlation value is displayed on the graph. (E) Kaplan-Meier curves comparing OS for patients defined as CD103\textsuperscript{high} and CD103\textsuperscript{low} in (C). Statistical significance was determined by Cox proportional hazard modeling. The HR and p-value are displayed within. HR, hazard ratio; IHC, immunohistochemistry; mUC, metastatic urothelial carcinoma; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed cell death ligand 1; RNAseq, RNA sequencing; TPM, transcripts per million.

CD103 IHC was then performed on a subset of tumors from IMvigor210 (n=91) to verify association with clinical outcome at the protein level. Based on the distribution of CD103+ cells in the tumor area across these patients, a ≥2% cut-off was selected for CD103 positivity (figure 4C). The frequency of CD103+ cells was correlated with ITGAE gene expression, as determined by bulk RNAseq (figure 4D). Patients were separated into CD103\textsuperscript{low} and CD103\textsuperscript{high} subgroups, based on the ≥2% cut-off identified. CD103\textsuperscript{high} patients (median OS: 17.9 months) demonstrated improved OS (HR=0.53, p=0.045) relative to CD103\textsuperscript{low} individuals (median OS: 9.5 months) (figure 4E). Thus, at both the transcriptional and protein

patients with ITGAE\textsuperscript{high} tumors treated with atezolizumab had significantly increased OS relative to their ITGAE\textsuperscript{low} counterparts (IMvigor210) (figure 4B and online supplemental figure S6B). Remarkably, high CD8A expression was not associated with increased OS in this cohort. In the randomized trial IMvigor211, ITGAE\textsuperscript{high} tumors demonstrated a modest improvement in OS compared with ITGAE\textsuperscript{low} tumors in patients treated with atezolizumab but not chemotherapy (online supplemental figure S6C), with the highest quartile demonstrating a trend toward increased OS in the atezolizumab-treated arm (online supplemental figure S6D), a phenomenon not observed with CD8A.
levels, CD103 expression in tumors was associated with better OS in patients treated with atezolizumab.

**DISCUSSION**

Tumor infiltration by CD8+ T cells is an essential step of the cancer immunity cycle. Recent single-cell studies have identified multiple subsets of intratumoral CD8+ T cells, including T_Rm cells which express high levels of checkpoint regulators, leading to their characterization as being either exhausted or dysfunctional. The functionality of tumor-infiltrating CD8+ T cells is controversial, and the relationships between exhausted and tissue-resident T cells remain poorly understood. Here, we show that T-cell exhaustion is associated with a tissue resident phenotype. Based on these observations, we propose a model (figure 5) whereby in the development of antitumor immunity, tumor antigen presentation and lymph node activation of T_SCM cells lead to T_Eff cell egress from lymph nodes and circulation into tumor tissue via blood. In response to tumor antigens and cytokines present in the tumor environment, these cells differentiate into T_Rm cells and secrete IFN-γ, causing the upregulation of IFN-γ-inducible genes such as PD-L1. The interplay between tumor reactive T_Rm activity and the paracrine induction of PD-L1 in tumor and antigen-presenting cells thus forms the basis of PD-L1-dependent adaptive immune resistance and may act to prevent activation-induced T-cell death. As such, PD-L1 biomarker status may indicate the existence of an ongoing CD103+ CD8+ T-cell immune response, consistent with our observed correlation between the frequency of Ki-67+ CD8+ T_Rm and PD-L1+ immune cells (online supplemental figure S1E).

While T_Rm tumor reactivity can be inferred based on overt phenotypic signs of chronic stimulation, the presumed dysfunctionality of these cells makes it unclear...
whether $T_{\text{RM}}$ activity is a proximal or distal biomarker relative to the unknown precise mode of action of PD-1/PD-L1 blockade. In a ‘reinvigoration’ or reversible exhaustion model, PD-1/PD-L1 checkpoint inhibition should function optimally in tumors infiltrated with exhausted cells. However, multiple studies suggest the presence of an epigenetically programmed terminally exhausted state enforced by TOX that is induced early upon chronic stimulation and unlikely to be reversible.\textsuperscript{73, 74} Alternatively, it has been shown in preclinical models that PD-1/PD-L1 checkpoint inhibition acts on self-renewing $T_{\text{SCM}}$ cells,\textsuperscript{75, 76} but the precise differentiation state and physiological compartment that immune checkpoint inhibition targets for clinical efficacy remains obscure. Importantly, multiple functional studies suggest that simply the expression of immune checkpoint regulators such as PD-1, TIM3, and LAG3 is insufficient in identifying cells that are inert or terminally exhausted and that CD8+ T cells expressing these markers produce the same, if not more, inflammatory cytokines than cells lacking checkpoints.\textsuperscript{77-81} Furthermore, tumor CD8+ $T_{\text{RM}}$ cells uniquely expressed CXCL13 (figure 3C,D), which has been shown in multiple studies to be a distinct functionality of ‘exhausted’ CD8+ T cells.\textsuperscript{3, 82} CXCL13 can contribute to tertiary lymphoid structure formation, which has been recently linked to immunotherapy response.\textsuperscript{83} Precise identification of the subset and phenotypic state that is most poised to directly respond to immunotherapy will require further investigation, though our study and others point to a potential role for tumor CD8+ $T_{\text{RM}}$ cells.

Recent studies have shown that following anti-PD-1 therapy, novel tumor antigen-specific (based on CD39 expression) TCR clones are expanded rather than clones that had been detected prior to treatment.\textsuperscript{41} The phenomenon of clonal replacement following checkpoint therapy does not preclude a ‘pre’ or ‘progenitor’ exhaustion model in which T cells that are clonally expanded in the tumor prior to treatment are still a relevant direct target of PD-1/PD-L1 blockade. Pre-exhausted cells may be ‘potentiatted’ and rescued from terminal exhaustion by immune checkpoint inhibition. Rather than being reinvigorated, implying further clonal expansion, pre-exhausted $T_{\text{RM}}$ cells already proliferating and involved in tumoricidal activity could potentially break the cycle of adaptive immune resistance induced by PD-1 signaling without expanding dramatically in numbers post-treatment. Potentiated tumor lysis could provide new tumor antigens (epitope spread) for dendritic cell capture in draining lymph nodes, subsequently generating a systemic immune response resulting in tumor infiltration with novel TCR clones. It is possible that sustained $T_{\text{RM}}$ -mediated antitumor activity causes clonal replacement to be a constant feature of the cancer immunity cycle that is accelerated, rather than induced de novo, by immune checkpoint inhibition.

Importantly, tumor signatures of immune reactivity or ‘exhaustion’ have not universally correlated with improved clinical outcomes.\textsuperscript{4-8} Studies in melanoma found patients with high numbers of TCF-1+ $T_{\text{SCM}}$ cells and low numbers of exhausted cells to have better outcomes than patients in whom this ratio is inverted.\textsuperscript{4} However, the $T_{\text{SCM}}$ phenotype, in contrast to tumor $T_{\text{RM}}$ cells, does not overtly display hallmarks of cellular activation, and thus tumor reactivity cannot be assumed unless proven by other methods.\textsuperscript{71} In highly immunogenic tumors, it is possible that a large fraction of CD8+ T cells, including $T_{\text{SCM}}$ cells, are tumor antigen-specific and poised to respond to checkpoint inhibition, but it is as yet unclear whether tumor $T_{\text{SCM}}$ content can serve as a biomarker in indications other than melanoma. In contrast, the $T_{\text{RM}}$ phenotype, and CD103 specifically, has been associated with improved OS in several cancers.\textsuperscript{10, 84} Our data revealed potential indication-specific differences in the predictive utility of ITGAE relative to CD8A (figure 4). This could reflect phenotypic differences in predominant CD8+ T cells between tumor types. In NSCLC, where both genes showed similar associations with OS (figure 4A), we observed a very high overlap of CD103 and CD8 (online supplemental figure S1B). In mUC, CD8+ CD103+ $T_{\text{RM}}$ cells were present at reduced frequencies relative to NSCLC (online supplemental figure S5C); thus, the elevated presence of CD8+ CD103– bystander cells may explain the superiority of ITGAE over CD8A as a biomarker of clinical response in this indication. As such, response to immunotherapy is not only connected to the extent of CD8+ T-cell infiltration in inflamed versus excluded tumors but also the quality and phenotype of the cells present. Our initial observation that classification as an inflamed tumor was closely tied to CD103 expression highlights these cells as key players in anti-tumor responses. The routine inclusion of CD103 as an immunotherapy biomarker will enable the extension of these observations to other indications that remain largely unexplored in this context such as pancreatic cancer, renal cell carcinoma, and lymphomas. Furthermore, we believe the quantification of proliferative (or Ki-67+) CD103+ $T_{\text{RM}}$ cells will have additional value in that these cells may be most proximal to the method of action of PD-L1 blockade and thus highly predictive of immunotherapy response.

Our studies have focused on $T_{\text{RM}}$ cells specifically within the primary tumor tissue. With the development and control of metastases being of significance to patient prognosis, a key question is whether CD103+ tumor antigen-specific $T_{\text{RM}}$ cells are able to leave the tumor and circulate to these secondary metastases or whether their tissue specificity is permanent. Recent preclinical evidence suggests that rather than being confined to tissue as a terminal state, $T_{\text{RM}}$ cells maintain plasticity and can rejoin the circulating pool of T cells as conventional memory cells.\textsuperscript{85} Identifying the phenotypes, clonality, and interplay of CD8+ T cells in these distant metastases will be of great importance in determining the long-term impact of $T_{\text{RM}}$ cells on cancer survival outcomes.

Overall, we have identified CD103 as a marker of CD8+ T-cell tumor infiltration, and demonstrated that these
cells exhibit an activated and proliferative phenotype characterized by clonal expansion. CD103 expression, both at the transcriptional and protein levels, associates with better response to checkpoint blockade. Future studies will be necessary to determine whether T BM activity is a proximal or distal biomarker of immune checkpoint inhibition and how exactly these cells contribute to anti-tumor responses post-therapy. Further reading material are listed in the supplemental material provided.

Author affiliations
1Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, California, USA
2Department of Cancer Immunology, Genentech Inc, South San Francisco, California, USA
3Department of Research Pathology, Genentech Inc, South San Francisco, California, USA
4Department of OMNI Biomarker Development, Genentech Inc, South San Francisco, California, USA
5Adaptive Biotechnologies Corp South San Francisco, South San Francisco, California, USA
6Department of OMNI Biomarker Development, Genentech Inc, South San Francisco, California, USA
7Department of Microchemistry, Proteomics, Lipidomics, and Next Generation Sequencing, Genentech Inc, South San Francisco, California, USA
8Analytical Biosciences Limited, South San Francisco, California, USA
9Ventana Medical Systems Inc, Tucson, Arizona, USA
10Bolt Biotherapeutics, Redwood City, California, USA
11Department of Biostatistics Oncology, Genentech Inc, South San Francisco, California, USA
12Barts Cancer Center, Queen Mary University, London, UK

Acknowledgements
We thank Valerie Quarmby, Hanjo Lim, Bartek Bossak, Jose Diaz, Paul Vu, Justin Low, Mehraban Koshraviani, and Mike Phan for mass cytometry reagent support. We acknowledge SMART-server for provision of graphic components used in the generation of the model figure. We thank Mary Keir for discussions on Integrin ex; We also thank Suvarna Gupta, Susan Flynn, and the Biosample Repository and Human Tissue Labs for tissue sample logistical support. We thank David Oh for providing dimensionality reduction coordinates for the bladder data.

Contributors
Conceptualization: RB, ASC, SM, JG and WOG; validation, RB and WOG; formal analysis: RB, ASC, NSP, TDW, AA-Y, JCH, WZ, EAE-G, HK and WOG; investigation: ASC, AS, PdA, SM, AA-Y, JC-Y, and MDR; resources: TP, ZM, EEK and PC; writing of the original draft: WOG, ASC and RB; writing (review and editing): all authors; visualization: RB, ASC, AS, TDW, STE and AA-Y; supervision: PSH, IM, WRM, JMcB and TP; project administration: RM, MK, MMcM, WZ, SM, AS, TDW and NSP were co-second authors.

Funding
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests
All authors except Thomas Powles are current or former employees of Roche.

Patient consent for publication
Not required.

Ethics approval
The authors complied with all ethical standards of the Roche Ethics Committee. Informed consent was obtained from all sampled individuals.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available in a public, open access repository. All data relevant to the study are included in the article or uploaded as supplementary information. All data from bulk RNA sequencing (RNAseq) of patients from the IMvigor211 clinical trial are available within the European Genome-Phenome Archive under accession number EGAS00001003556 and have also been previously published. The resulting data from mass cytometry analyses are deposited in Flowrepository.org. Single-cell RNA and TCR sequencing data used in these studies have previously been published and are available within EGA under studies EGAS0000103993 and EGAS0000103994 and datasets EGAD00001005464 and EGAD00001005465. The bladder tumor dataset obtained from Oh et al. 202061 is publicly available in the NCBI GEO database under accession GSE149652. Coordinates for generation of the UMAP were obtained from the authors. There are restrictions to the availability of bulk RNAseq datasets from patients enrolled in OAK and IMvigor211 clinical trials, but a normalized expression matrix for ITGAE and CD8A, the only genes included from these trials in these studies, is provided as a supplementary file.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
William E O’Gorman http://orcid.org/0000-0003-0753-3355

REFERENCES
1. Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 2015;36:265–76.
2. Gong J, Chehrazi-Rafie A, Reddi S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 2018:6:8.
3. van der Leun AM, Thommen DS, Schumacher TN. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer 2020;20:218–32.
4. Verma V, Shrimali RK, Ahmad S, et al. PD-1 blockade in subpruned CD8 cells induces dysfunctional PD-1+CD38+ cells and anti-PD-1 resistance. Nat Immunol 2019;20:1231–43.
5. Mazzasci G, Madeddu D, Falco A, et al. Low PD-1 expression in cytotoxic CD8+ tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value. Clin Cancer Res 2018;24:407–19.
6. Kim H-D, Song G-W, Park S, et al. Association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma. J Immunother Cancer 2019;7:331.
7. Ma J, Zheng B, Goswami S, et al. PD1+ CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J Immunother Cancer 2019;7:331.
8. Datar I, Sammamed MF, Wang J, et al. Expression analysis and significance of PD-1, LAG-3, and Tim-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis. Clin Cancer Res 2019;25:4663–73.
9. Sade-Feldman M, Yizhak K, Bjorgaard SL, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 2018;175:998–1013.
10. Amsen D, van Gisbergen KPJM, Hombrick P, et al. Tissue-resident memory T cells at the center of immunity to solid tumors. Nat Immunol 2018;19:538–46.
11. Masopust D, Soerens AG. Tissue-resident T cells and other resident leukocytes. Annu Rev Immunol 2019;37:521–46.
12. Farber DL, Yudani NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol 2014;14:24–35.
13. Fransen NL, Hsiao C-C, van der Poel M, et al. Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions. Brain 2020;143:1714–30.
14. Sasson SC, Gordon CL, Christo SN, et al. Local heroes or villains; tissue-resident memory T cells in human health and disease. Cell Mol Immunol 2020;17:11–22.
15. Zundler S, Becker E, Spoceinska M, et al. Hobit- and Blimp-1-driven CD4+ tissue-resident memory T cells control chronic intestinal inflammation. Nat Immunol 2019;20:288–300.
16. Hadley GA, Higgins JMG. Integrin αEβ7: molecular features and functional significance in the immune system. Adv Exp Med Biol 2014;819:97–110.
Patients and Are Tumor- Reactive Lymphocytes Enriched With Tc17.  

Cell Rep Med 2020;1:100127.

44 Wu TD, Madireddi S, de Almeida PE, et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 2020;579:272.

45 Manthasasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 2018;554:544–8.

46 Oh DY, Kwak SS, Raju SS, et al. Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 2019;185:1612–3.

47 Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2020;395:1900–9.

48 Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:747–57.

49 Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (oak): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255–65.

50 Hegin PS, Karanikas V, Evers S. The where, when, and how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res 2016;22:1865–74.

51 Mackay LK, Minnich M, Kragten NAM, et al. Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes. Science 2016;352:459–63.

52 Kavurma MM, Khanjan LM. Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ 2003;10:36–44.

53 Ng SS, De Labastida Rivera F, Yan J, et al. The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. Nat Immunol 2020;21:1205–18.

54 Becht E, McNlness L, Healy J, et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat Biotechnol 2018;37:38–44.

55 Molodtsov A, Turk MJ. Tissue resident CD8 memory T cell responses in cancer and autoimmunity. Front Immunol 2018;9:2810.

56 Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003;101:2711–20.

57 Zhao Y, Shao Q, Peng G. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. Cell Mol Immunol 2020;17:27–35.

58 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–64.

59 Hoekstra ME, Bornes L, Djikgraaf FE, et al. Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFNγ. Nat Cancer 2020;1:291–301.

60 Oja AE, Piat B, van der Zwan D, et al. Functional heterogeneity of CD4+ tumor-infiltrating lymphocytes with a resident memory phenotype in NSCLC. Front Immunol 2018;9:2654.

61 Bratke K, Kuepper M, Bada B, et al. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood. Eur J Immunol 2008;38:1907–18.

62 Huang M, Wang H, Xu Y, et al. IncRNA MALAT1 binds chromatin remodeling subunit BRG1 to epigenetically promote inflammation-related hepatocellular carcinoma progression. Oncotarget 2018;9:1–14.

63 Siddiqui I, Schaeuble K, Chenunpati V, et al. Intratumoral Tcf11“PD-1+”CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 2019;50:195–211.

64 Gherardin NA, Souter MN, Koay H-Br, et al. Human blood MAIT cell subsets defined using MR1 tetramers. Immunol Cell Biol 2018;96:507–25.

65 Khan O, Giles JR, McDonald S, et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 2019;571:211–6.

66 Scott AG, Dündar F, Zumbo P, et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 2019;571:270–4.

67 Guo X, Zhang Y, Zheng L, et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med 2018;24:978–83.

68 Trosch I, Izar Prakash SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016;352:189–96.
Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 2019;176:775–89.

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1–10.

Blank CJ, Haining WN, Held W, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol 2019;19:665–74.

Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 2015;5:915–9.

Philip M, Fairchild L, Sun L, et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 2017;545:452–6.

Pauken KE, Sammons MA, Odorizzi PM, Blank CU, Haining WN, Held W, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol 2019;20:326–36.

Im SJ, Hashimoto M, Gerner MY, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 2016;537:417–21.

Clarke J, Panwar B, Madrigal A, Epstein-Barr virus infection in vivo. PLoS Pathog 2019;15:e1007748.

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1–10.

Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 2015;5:915–9.

Philip M, Fairchild L, Sun L, et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 2017;545:452–6.

Pauken KE, Sammons MA, Odorizzi PM, Blank CU, Haining WN, Held W, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol 2019;19:665–74.

Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 2015;5:915–9.

Philip M, Fairchild L, Sun L, et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 2017;545:452–6.

Pauken KE, Sammons MA, Odorizzi PM, Blank CU, Haining WN, Held W, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol 2019;19:665–74.

Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 2015;5:915–9.

Philip M, Fairchild L, Sun L, et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 2017;545:452–6.